Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: Single-center experience

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Livi, Lorenzo ^a   Bonomo, Pierluigi ^a   Meattini, Icro ^a   Simontacchi, Gabriele ^a   Greto, Daniela ^a   Desideri, Isacco ^a   Meacci, Fiammetta ^a   Scotti, Vieri ^a   Cecchini, Sara ^a   Nori, Jacopo ^a   Sanchez, Luis Jose ^a   Orzalesi, Lorenzo ^a   Paiar, Fabiola ^a   Biti, Gianpaolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Bevacizumab; Breast cancer; Chemotherapy; Metastatic breast carcinoma; Paclitaxel

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SENSORY NEUROPATHY; TIME TO TREATMENT; TREATMENT FAILURE; VENOUS THROMBOEMBOLISM;

EID: 84871702537     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0434-2     Document Type: Article

References (15)

1. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-76.
2. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3229-47.
3. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252-60.
4. Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controller trials. Oncologist. 2010;15:1179-91.
5. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol. 2011;22:595-602.
6. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer. 2005;93:293-301.
7. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843-9.
8. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369-72.
9. Yanagisawa M, Yorozu K, Kurasawa M, et al. Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs. 2010;21:687-94.
10. Chan A, Miles DW, Pivot X. Bevacizumab in combination with taxanes for the first line treatment of metastatic breast cancer. Ann Oncol. 2010;21:2305-15.
11. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2010;122:1-7.
12. Pritchard KI, Thomssen C, Pierga JY, et al. Final overall survival results, including analysis of patients with triple-negative disease and aged ≥ 70 years, from the ATHENA study evaluating first-line bevacizumab- containing therapy for locally recurrent/metastatic breast cancer. Cancer Res. 2010;70(24 suppl):236s.
13. Cortes J, Calvo V, Ramirez-Merino N, et al. Adverse event risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol. 2012;23:1130-7.
14. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642-9.
15. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26:1987-92.